Topic: Cancer research

Seminar
2 seminars
Conference
1 conference
Grant
1 grant

Domains featuring this topic

Explore the domains where this topic appears.

Conference

AACR Annual Meeting 2027

Orlando, FL, USA
Apr 2, 2027

The American Association for Cancer Research's flagship annual meeting, themed 'Delivering Discovery Science: The Bridge to Breakthrough Therapeutics', at the Orange County Convention Center in Orlando, Florida.

Grant

Pre-doctoral Research Bursary

Cancer Research UK
Sep 24, 2026

Cancer Research UK offers short-term support for clinicians, nurses and allied health professionals to gain early-career cancer-research experience and generate preliminary data before applying for a PhD or MD fellowship.

SeminarMicrobiologyRecording

Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer

Jorge L. Galeano Niño
Fred Hutchinson Cancer Research Center
Feb 16, 2023
SeminarChemistry

Radiopharmaceutical evaluation of novel bifunctional chelators and bioconjugates for tumour imaging and therapy

Manja Kubeil
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden- Rossendorf (HDZR), Germany
Oct 12, 2022

Bispidines (3,7-diazabicyclo[3.3.1]nonane) and their derivatives act as bifunctional chelators (BFC), combining the advantages of multidentate macrocyclic and acyclic ligands e.g. high kinetic inertness, rapid radiolabelling under mild conditions. This bicyclic chelator system shows a great diversity in terms of its denticity and type of functional groups, yielding a wide range of multidentate ligands that can bind a variety of different metal ions. In addition, they allow a facile functionalisation of targeting molecules such as peptides, peptidomimetics, and bispeci􀄀c antibodies. Herein, examples of various bispidine complexes labelled with [64Cu]Cu2+, [111In]In3+, [ 177Lu]Lu3+ or [ 225Ac]Ac3+ will be presented which provide a picture of how different substituents in􀄁uence the coordination mode. Target-speci􀄀c radiolabelled bispidine-based conjugates (e.g. peptides, antibody fragments, antibodies) investigated in vivo by positron emission or single-photon emission computed tomography will be presented and discussed in terms of their suitability for nuclear medicine applications.

We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.